DSSG Group: Gynaecological

People with endometrial cancer who are planned to receive external-beam radiotherapy as part of their cancer treatment.

The MICRO-GI study aims to find out whether it is practical and acceptable for women receiving pelvic radiotherapy for endometrial cancer to take daily probiotic supplements and receive personalised dietary counselling.

Ovarian, peritoneal, or fallopian tube cancer

The purpose of this trial is to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

Cervical cancer that has returned or spread to other parts of the body after treatment and is not treatable by surgery and/or radiation

The purpose of this study is to learn:

About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and
If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Platinum-Sensitive Recurrent Ovarian Cancer and who have progressed after first line platinum-based therapy and have not progressed after second-line maintenance treatment.

The trial is testing the efficacy of the investigational drug “Sacituzumab Tirumotecan (MK-2870)” during maintenance treatment, with or without Bevacizumab, compared to Standard of Care treatment.

Primary advanced or returned Endometrial cancer whose mismatch repair system is working normally and who are starting their first maintenance treatment.

The trial is testing a new combination of treatments for people with advanced or recurring Endometrial Cancer whose cancer has a “normal” mismatch-repair system (so-called “mismatch repair proficient” or pMMR).
Specifically, researchers want to see if using a combination of two drugs — Sacituzumab Tirumotecan (sometimes “sac-TMT”) plus Pembrolizumab — works better than giving pembrolizumab alone.

Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

The purpose of the study is to assess the efficacy of TORL-1-23 administered as monotherapy in women with advanced, platinum-resistant ovarian cancer whose tumors express the claudin-6 (CLDN6) biomarker. The study will also evaluate the overall safety and tolerability of TORL-1-23 and its potential therapeutic effects in this patient population

Vulvar Cancer

This research aims to understand the long-term impact of vulvar cancer and its treatments on various aspects of a woman’s life, including physical health, emotional well-being, and sexual functioning.

Recurrent (previously treated) low grade serous ovarian cancer (LGSOC) who have progressed on a prior platinum-based therapy

The purpose of the study is to assess how avutometinib plus defactinib compares to the standard
treatments for LGSOC. The study will measure effectiveness, including overall response rate (how well the
combination reduces tumor size) and safety. The study will also include quality of life assessments by the
patient.

First platinum sensitive relapsed ovarian cancer

Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer. Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer. This study aims to improve upon the contemporary AGO score by including additional clinical variables like circulating HE4 and CA125 levels to predict surgical outcome at secondary cytoreduction.